File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1097/01.tp.0000239343.01775.54
- Scopus: eid_2-s2.0-33751517664
- PMID: 17130783
- WOS: WOS:000242461500012
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: A negative regulatory role in mouse cardiac transplantation for a splice variant of CD80
Title | A negative regulatory role in mouse cardiac transplantation for a splice variant of CD80 |
---|---|
Authors | |
Keywords | Alternative splicing B7 CD80 Costimulation Tolerance |
Issue Date | 2006 |
Publisher | Lippincott Williams & Wilkins. The Journal's web site is located at http://www.transplantjournal.com |
Citation | Transplantation, 2006, v. 82 n. 10, p. 1334-1341 How to Cite? |
Abstract | BACKGROUND. Members of the B7 costimulatory protein family (CD80 and CD86) play a determining role in allograft rejection. Both CD80 and CD86 have naturally occurring splice variants whose roles in transplantation are unknown. Full length CD80 has two immunoglobulin (Ig)-like domains in the extracellular portion, IgC and IgV. In mouse, the isoform IgV-CD80 lacks the IgC-like domain. Here we analyzed the role of mouse IgV-CD80 in heart allograft rejection and search for equivalent splice variants in human. METHODS. Mice made deficient for full-length CD80 but which retain expression of the shorter IgV-CD80 (CD80 mice) were used as donor or recipient of a heart allograft. Recipient animals were untreated or pretreated with alloantigen expressing cells and/or treated with CD80 and CTLA4 monoclonal antibodies (mAbs). RESULTS. Recipients expressing IgV-CD80 but not full length CD80 exhibited a slight prolongation in survival of either wild-type (Wt) or CD80 grafts. More dramatically, CD80 animals pretreated with donor alloantigen exhibited permanent graft survival, whereas their Wt counterparts rejected their grafts with a median survival of 24 days. This prolonged survival was due to the expression of IgV-CD80 in recipients since treatment with CD80 mAb abrogated the beneficial effect observed. We identified and report here a similar isoform of CD80 from human cDNA encoding a putative soluble, IgV-containing protein. CONCLUSIONS. IgV-CD80 bearing recipients show enhanced allograft survival especially after donor alloantigen pretreatment. This together with data from other species suggests that regulation delivered by splice variants of CD80 significantly modulates immunity and may be common across the species. © 2006 Lippincott Williams & Wilkins, Inc. |
Persistent Identifier | http://hdl.handle.net/10722/172932 |
ISSN | 2023 Impact Factor: 5.3 2023 SCImago Journal Rankings: 1.371 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bugeon, L | en_US |
dc.contributor.author | Wong, KK | en_US |
dc.contributor.author | Rankin, AM | en_US |
dc.contributor.author | Hargreaves, REG | en_US |
dc.contributor.author | Dallman, MJ | en_US |
dc.date.accessioned | 2012-10-30T06:25:52Z | - |
dc.date.available | 2012-10-30T06:25:52Z | - |
dc.date.issued | 2006 | en_US |
dc.identifier.citation | Transplantation, 2006, v. 82 n. 10, p. 1334-1341 | en_US |
dc.identifier.issn | 0041-1337 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/172932 | - |
dc.description.abstract | BACKGROUND. Members of the B7 costimulatory protein family (CD80 and CD86) play a determining role in allograft rejection. Both CD80 and CD86 have naturally occurring splice variants whose roles in transplantation are unknown. Full length CD80 has two immunoglobulin (Ig)-like domains in the extracellular portion, IgC and IgV. In mouse, the isoform IgV-CD80 lacks the IgC-like domain. Here we analyzed the role of mouse IgV-CD80 in heart allograft rejection and search for equivalent splice variants in human. METHODS. Mice made deficient for full-length CD80 but which retain expression of the shorter IgV-CD80 (CD80 mice) were used as donor or recipient of a heart allograft. Recipient animals were untreated or pretreated with alloantigen expressing cells and/or treated with CD80 and CTLA4 monoclonal antibodies (mAbs). RESULTS. Recipients expressing IgV-CD80 but not full length CD80 exhibited a slight prolongation in survival of either wild-type (Wt) or CD80 grafts. More dramatically, CD80 animals pretreated with donor alloantigen exhibited permanent graft survival, whereas their Wt counterparts rejected their grafts with a median survival of 24 days. This prolonged survival was due to the expression of IgV-CD80 in recipients since treatment with CD80 mAb abrogated the beneficial effect observed. We identified and report here a similar isoform of CD80 from human cDNA encoding a putative soluble, IgV-containing protein. CONCLUSIONS. IgV-CD80 bearing recipients show enhanced allograft survival especially after donor alloantigen pretreatment. This together with data from other species suggests that regulation delivered by splice variants of CD80 significantly modulates immunity and may be common across the species. © 2006 Lippincott Williams & Wilkins, Inc. | en_US |
dc.language | eng | en_US |
dc.publisher | Lippincott Williams & Wilkins. The Journal's web site is located at http://www.transplantjournal.com | en_US |
dc.relation.ispartof | Transplantation | en_US |
dc.subject | Alternative splicing | - |
dc.subject | B7 | - |
dc.subject | CD80 | - |
dc.subject | Costimulation | - |
dc.subject | Tolerance | - |
dc.subject.mesh | Alternative Splicing - Genetics | en_US |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Antigens, Cd80 - Genetics | en_US |
dc.subject.mesh | Genetic Variation | en_US |
dc.subject.mesh | Graft Survival - Immunology | en_US |
dc.subject.mesh | Heart Transplantation - Immunology | en_US |
dc.subject.mesh | Homeostasis | en_US |
dc.subject.mesh | Mice | en_US |
dc.subject.mesh | Mice, Inbred C3h | en_US |
dc.subject.mesh | Mice, Knockout | en_US |
dc.subject.mesh | Models, Animal | en_US |
dc.title | A negative regulatory role in mouse cardiac transplantation for a splice variant of CD80 | en_US |
dc.type | Article | en_US |
dc.identifier.email | Wong, KK: kkywong@hkucc.hku.hk | en_US |
dc.identifier.authority | Wong, KK=rp01392 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1097/01.tp.0000239343.01775.54 | en_US |
dc.identifier.pmid | 17130783 | - |
dc.identifier.scopus | eid_2-s2.0-33751517664 | en_US |
dc.identifier.hkuros | 125294 | - |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-33751517664&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 82 | en_US |
dc.identifier.issue | 10 | en_US |
dc.identifier.spage | 1334 | en_US |
dc.identifier.epage | 1341 | en_US |
dc.identifier.isi | WOS:000242461500012 | - |
dc.publisher.place | United States | en_US |
dc.identifier.scopusauthorid | Bugeon, L=6602173647 | en_US |
dc.identifier.scopusauthorid | Wong, KK=24438686400 | en_US |
dc.identifier.scopusauthorid | Rankin, AM=7103152390 | en_US |
dc.identifier.scopusauthorid | Hargreaves, REG=7007184704 | en_US |
dc.identifier.scopusauthorid | Dallman, MJ=35473592200 | en_US |
dc.identifier.issnl | 0041-1337 | - |